Dusigitumab
From The Right Wiki
Jump to navigationJump to search
Chemical compoundTemplate:SHORTDESC:Chemical compound
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Dusigitumab" – news⧼Dot-separator⧽newspapers⧼Dot-separator⧽books⧼Dot-separator⧽scholar⧼Dot-separator⧽JSTOR (February 2023) (Learn how and when to remove this message) |
Pharmaceutical compoundTemplate:SHORTDESC:Pharmaceutical compound
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IGF2 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6372H9824N1700O2016S54 |
| Molar mass | 144233.81 g·mol−1 |
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGF2.[1][2] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.[3] Its development has been discontinued.[2]
References
- ↑ "Dusigitumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
- ↑ 2.0 2.1 Osher E, Macaulay VM (August 2019). "Therapeutic Targeting of the IGF Axis". Cells. 8 (8): 895. doi:10.3390/cells8080895. PMC 6721736. PMID 31416218.
- ↑ "Dusigitumab - MedImmune". AdisInsight. Springer Nature Switzerland AG.
| Angiopoietin |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CNTF |
| ||||||||||
| EGF (ErbB) |
| ||||||||||
| FGF |
| ||||||||||
| HGF (c-Met) |
| ||||||||||
| IGF |
| ||||||||||
| LNGF (p75NTR) |
| ||||||||||
| PDGF |
| ||||||||||
| RET (GFL) |
| ||||||||||
| SCF (c-Kit) |
| ||||||||||
| TGFβ |
| ||||||||||
| Trk |
| ||||||||||
| VEGF |
| ||||||||||
| Others |
| ||||||||||
| Stub icon | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
| Stub icon | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://rightwiki.org/index.php?title=Dusigitumab&oldid=15879074"
Hidden categories:
- Articles with short description
- Short description with empty Wikidata description
- Articles needing additional references from February 2023
- All articles needing additional references
- Drugs not assigned an ATC code
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles containing unverified chemical infoboxes
- All stub articles
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs